Latest From Merus NV
Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.
When approved therapies target the same antigens as the investigational bispecific antibody, FDA may request a comparative clinical trial, draft guidance notes.
EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule EMB01, an EGFR-cMET bispecific antibody.
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
- Antisense, Oligonucleotides
- Therapeutic Areas
- Merus BV
- Western Europe
- Parent & Subsidiaries
- Merus NV
- Senior Management
Bill Lundberg, MD, CEO
Mark Throsby, PhD, EVP, CSO
Hui Liu, PhD, EVP, CBO
L. Andres Sirulnik, MD, PhD, EVP, CMO
- Contact Info
Phone: (31) 85 016 2500
Utrecht , 3584 CM
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.